Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

Biotechnology

Healthcare
$2.83 +1.45%

+$0.04 today

Market cap
$1.76B
Beta
1.00
P/E (TTM)
-3.0
EPS (TTM)
-$1.06
52W Low $2.77High $7.18

Volume 41.13M

Average 15.60M

RXRX Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Recursion Pharmaceuticals, Inc.NASDAQ: RXRX

Deferred Revenue · Q2 FY2026 · quarter ended Jun 2026

Deferred revenue falls 30.5% from a year ago

Deferred revenue stood at $27.59M at the end of Q2 FY2026, down 30.5% from a year earlier and down 15.9% from the prior quarter. Over 3 fiscal years it compounded at -12.8% a year.

Context

  • Deferred revenue amounted to 2.3% of total assets at the end of Q2 FY2026, down 0.8 pp from a year earlier.
  • Deferred revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -30.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$27.59M-15.9% QoQ
Last fiscal yearDec 2025
$37.61M-39.1% YoY
Year agoJun 2025
$39.69M-30.5% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.5%——
1 year-39.1%——
3-year CAGR-12.8%——
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
37.61M USD
Year-over-year change
-39.1%
4-year CAGR
+39.3%

Deferred Revenue vs competitors

How RXRX compares with its peers on the latest reported figures

  • RXRX's Jun 2026 deferred revenue of $27.59M is the highest of the 4 companies compared; the peer median is $0.
  • Deferred revenue amounts to 2.3% of total assets for RXRX, versus a peer median of 0.0%.
RXRX Competitors Peer median
Deferred Revenue for RXRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RXRXRecursion Pharmaceuticals, Inc.Jun 2026$27.59M -30.5%-12.8%2.3%
RLAYRelay Therapeutics, Inc.Jun 2026$0 ——0.0%
DNLIDenali Therapeutics Inc.Jun 2026$0 ——0.0%
MAZEMaze Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding RXRX) $0——0.0%

Competitors are the stored peer set for RXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents285.12M549.91M391.57M594.35M743.29M
Short-term Investments231.45M0000
Net Receivables9.09M2.75M3.09M49.17M24.65M
Inventory00000
Other Current Assets9.07M17.15M43.48M70.75M33.16M
Total Current Assets534.72M569.81M438.14M714.27M812.85M
Property, Plant & Equipment (Net)64.73M121.45M120.17M233.21M169.48M
Goodwill801K801K52.06M148.87M162.16M
Intangible Assets1.39M1.31M36.44M335.86M309.9M
Long-term Investments0005.63M0
Tax Assets0001.93M957K
Other Non-current Assets8.72M7.92M6.89M8.83M18.79M
Total Non-current Assets75.63M131.47M215.56M734.33M661.29M
Total Assets610.35M701.29M653.7M1.45B1.47B
Account Payables2.82M4.59M3.95M21.61M18.12M
Short-term Debt90K97K41K8.43M9.09M
Tax Payables00000
Deferred Revenue10M56.73M36.43M61.77M37.61M
Other Current Liabilities11.74M20.43M23.75M50.85M31.77M
Total Current Liabilities46.66M100.27M93.17M187.47M147.71M
Long-term Debt633K536K1.1M19.02M9.56M
Deferred Tax Liabilities001.34M16.58M23.26M
Deferred Revenue (Non-current)6.67M70.26M51.24M118.77M114.01M
Other Non-current Liabilities4.11M004.73M2.08M
Total Non-current Liabilities20.75M115.22M97.09M226.34M195.56M
Total Liabilities67.41M215.48M190.26M413.82M343.27M
Common Stock2K2K2K4K5K
Retained Earnings(400.08M)(639.56M)(967.62M)(1.43B)(2.08B)
Accumulated OCI(126K)00(7.64M)36.72M
Other Stockholders Equity00000
Minority Interest00000
Total Equity542.94M485.81M463.44M1.03B1.13B
Total Debt11.48M51.01M50.67M108.49M77.97M
Net Debt(273.64M)(498.91M)(340.89M)(485.86M)(665.33M)

Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

Intrinsic Alpha fair value

Locked

Current Price

$2.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.